ストックスクリーナーアプリを入手
10.80
2.26%
-0.25
前日終値:
$11.05
開ける：
$11.17
24時間の取引高:
2.16M
Relative Volume:
1.23
時価総額：
$1.27B
収益：
$260.81M
当期純損益:
$20.48M
株価収益率:
83.08
EPS:
0.13
ネットキャッシュフロー:
$22.67M
1週間 パフォーマンス:
-3.23%
1か月 パフォーマンス:
+7.30%
6か月 パフォーマンス:
+3.65%
1年 パフォーマンス:
-11.26%
1日の値動き範囲:
$10.76
$11.26
1週間の範囲:
$10.76
$11.29
52週間の値動き範囲:
$9.20
$14.63
Dynavax Technologies Corp Stock (DVAX) Company Profile
名前
Dynavax Technologies Corp
セクター
電話
(510) 848-5100
住所
2100 POWELL STREET, EMERYVILLE, CA
DVAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DVAX
Dynavax Technologies Corp
|
10.80 | 1.30B | 260.81M | 20.48M | 22.67M | 0.13 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | Goldman | Neutral → Sell |
| 2024-02-01 | 開始されました | Goldman | Neutral |
| 2022-09-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-01-06 | 再開されました | Goldman | Buy |
| 2021-08-06 | 開始されました | Goldman | Buy |
| 2020-08-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-15 | 開始されました | Evercore ISI | Outperform |
| 2019-10-18 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-11 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-02-27 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-05-10 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-03-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2017-09-25 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-07-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-07-31 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-05-09 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2016-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-04-27 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2013-11-25 | アップグレード | MLV & Co | Hold → Buy |
| 2013-02-25 | ダウングレード | MLV & Co | Buy → Hold |
| 2012-11-16 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Dynavax Technologies Corp (DVAX) 最新ニュース
Is Dynavax Technologies Corporation (DYF1) stock a defensive play amid uncertainty2025 Trading Volume Trends & Accurate Trade Setup Notifications - newser.com
Dynavax (Nasdaq: DVAX) to Join Evercore Healthcare Conference Fireside Chat on Dec. 2 - Stock Titan
Why Dynavax Technologies Corporation (DYF1) stock remains top ratedRate Hike & Low Risk Entry Point Tips - newser.com
Can Dynavax Technologies Corporation stock deliver consistent earnings growthWeekly Risk Summary & Precise Trade Entry Recommendations - newser.com
Is Dynavax Technologies Corporation showing signs of accumulation2025 Price Targets & Long-Term Investment Growth Plans - newser.com
Why Dynavax Technologies Corporation (DYF1) stock fits value portfoliosTake Profit & Technical Pattern Based Buy Signals - newser.com
Campbell & CO Investment Adviser LLC Sells 24,624 Shares of Dynavax Technologies Corporation $DVAX - Defense World
Can Dynavax Technologies Corporation stock reach $100 price targetSell Signal & Smart Allocation Stock Tips - newser.com
How Dynavax Technologies Corporation stock responds to policy changesWeekly Market Report & Low Drawdown Momentum Ideas - newser.com
Vaxart, Inc. Enters Exclusive License Agreement with Dynavax for COVID-19 Oral Vaccine Candidate, Completes Phase 2b Enrollment and Reports Q3 2025 Financial Results - Quiver Quantitative
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results - Yahoo Finance
What institutional flow reveals about Dynavax Technologies CorporationWeekly Profit Report & Low Drawdown Investment Ideas - newser.com
Is Dynavax Technologies Corporation (DYF1) stock protected from inflationJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
What dividend safety score for Dynavax Technologies Corporation stockInflation Watch & Verified Technical Signals - newser.com
What analysts say about Dynavax Technologies Corporation DYF1 stockDividend Growth Stocks & Trusted Financial Advisors at No Cost - earlytimes.in
What MACD and RSI say about Dynavax Technologies CorporationDollar Strength & Growth Focused Investment Plans - newser.com
Dynavax Technologies Corporatio (DVAX) Stock Forecasts - Yahoo Finance
Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2025 Earnings Call Transcript - Insider Monkey
Why Dynavax Technologies (DVAX) Is Up 5.7% After Launching a $100 Million Buyback and Raising Guidance - Yahoo Finance
Dynavax targets 60% U.S. hepatitis B market share by 2030 amid new COVID-19 vaccine deal and expanded share repurchase - MSN
Predicting Dynavax Technologies Corporation trend using moving averagesJuly 2025 Update & Fast Exit Strategy with Risk Control - newser.com
Will Dynavax Technologies Corporation stock remain a Wall Street favoriteWeekly Gains Summary & Weekly Breakout Stock Alerts - newser.com
Chart overlay techniques for tracking Dynavax Technologies CorporationEarnings Overview Report & Low Risk High Win Rate Picks - newser.com
Dynavax posts 13% rise in HEPLISAV-B revenue, announces $100 million buyback - Investing.com Nigeria
Dynavax Technologies: Q3 Earnings Snapshot - ctinsider.com
Using data tools to time your Dynavax Technologies Corporation exit2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Will Dynavax Technologies Corporation price bounce be sustainablePortfolio Return Report & Smart Allocation Stock Tips - newser.com
Dynavax Technologies Corp (DVAX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Dynavax Technologies Corp (DVAX) 財務データ
収益
当期純利益
現金流量
EPS
6.17%
0.67%
大文字化:
|
ボリューム (24 時間):